Pharmaceuticals, Biotechnology and Life Sciences
LEXINGTON, Mass.–(BUSINESS WIRE)–$CNCE #CNCE—Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will host a conference call and webcast event…
DUBLIN & BURLINGAME, Calif.–(BUSINESS WIRE)–ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, will present…
Backing will propel PAI’s market leadership position and help capitalize on growth opportunities NEW YORK–(BUSINESS WIRE)–Enhanced Healthcare Partners (“EHP”), a…
Positive interim results announced from Phase 1 CMV vaccine (mRNA-1647) study Positive interim results announced from Phase 1 mRNA encoding…
BETHESDA, Md.–(BUSINESS WIRE)–#AD–India Globalization Capital, Inc. (NYSE American: IGC) today announced financial results for the quarter ended September 30, 2019,…
New financing will enable the company to expand in the US its phase II clinical trial ACTIMIS for its drug…
– Third-Quarter Revenue of $668.0 Million – – Third-Quarter GAAP Earnings per Share of $1.46 and Non-GAAP Earnings per Share…
– Results Continue to Demonstrate Statistically Significant Advantages of Descovy® Over Truvada® for Study Measurements of Bone and Renal Safety…
Sandoz Tuesday said it got approval from US Food and Drug Administration for its biosimilar Ziextenzo, which is in particularly significant since Sandoz short-acting filgrastim Zarxio is the first biosimilar to surpass its reference biologic in US market share.
‒ Expands Amneal’s Central Nervous System (CNS) Focused Development Pipeline with Orphan Drug ‒ BRIDGEWATER, N.J.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE:…